Skip to main content
. 2021 Oct 19;22(20):11253. doi: 10.3390/ijms222011253

Figure 3.

Figure 3

Schematic illustration of the potential compounds that target the dysfunction of mitochondrial structure, fragmentation and biogenesis as well as mPTP opening and mitochondrial antioxidant capacity in AKI and CKD. AKI: acute kidney injury; CKD: chronic kidney disease; ROS: reactive oxygen species. mPTP: mitochondrial permeability transition pore; CSA: Cyclosporine-A; TDZD-8: 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione; CoQ10: Coenzyme Q10 MitoQ: mitochondrial coenzyme Q; SkQR1: 10-(6′-plastoquinonyl) decylrhodamine 19.